MaxLife Technologies Inc. dba Maxlife
FDA issued a warning letter to MaxLife Technologies Inc. dba Maxlife (Irvine, CA) on February 20, 2026, after reviewing their website in December 2025 and finding false or misleading claims about compounded semaglutide and tirzepatide products. The company falsely labeled products with the 'Maxlife' brand as if it were the compounder, and made multiple claims that the compounded drugs were 'FDA-approved' or equivalent to FDA-approved branded products, when compounded drugs are not FDA-approved. FDA found the products misbranded under FDCA sections 502(a) and 502(bb), and demanded a written corrective response within 15 working days, warning that failure to comply may result in seizure or injunction.
Flagged claims (6)
Active ingredients in Mounjaro® & Zepbound®
generic compounded medication
With the same active ingredient as Mounjaro® and Zepbound®, this treatment has been clinically tested and FDA-approved for effective weight management.
Active ingredients in Ozempic® & Wegovy®
With the same active ingredient as Wegovy® and Ozempic®, this treatment has been clinically tested and FDA-approved for effective weight management.
FDA Approved
Required actions (5)
Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)'s Office of Compliance describing the specific steps you have taken to address any violations.
Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].
Identifying the entities that produce the compounded products offered on your website;
Providing a representative sample of labeling for such products;
Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.
Does your site contain similar claims?
The free site audit scans your whole site against every entry in this Atlas. Most glp-1 / weight loss sites match 3-6 patterns.
Run my free site auditWant this watched for you? Free monthly monitoring re-scans your site against the Atlas ruleset and emails you when new flagged wording appears, and your site gets the "Compliance Monitored" seal. Start free monitoring.
Worried about one specific page, ad, or email? Paste it into the free Claim Checker and see what the FDA and FTC would flag, with the precedent next to each one. No email required.
Check specific copy in the Claim Checker